Laura De Ramon
Barcelona, CT 08907, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Dual and Opposite Costimulatory Targeting with a Novel Human Fusion Recombinant Protein Effectively Prevents Renal Warm Ischemia Reperfusion Injury and Allograft Rejection in Murine Models.
Journal: International journal of molecular sciences
Published: December 30, 2020
The gene silencing of IRF5 and BLYSS effectively modulates the outcome of experimental lupus nephritis.
Journal: Molecular therapy. Nucleic acids
Published: October 14, 2020
In vivo CD40 Silencing by siRNA Infusion in Rodents and Evaluation by Kidney Immunostaining.
Journal: Bio-protocol
Published: September 30, 2020
The double edge of anti-CD40 siRNA therapy: It increases renal microcapillar density but favours the generation of an inflammatory milieu in the kidneys of ApoE -/- mice.
Journal: Journal of inflammation (London, England)
Published: April 15, 2019
The Costimulatory Pathways and T Regulatory Cells in Ischemia-Reperfusion Injury: A Strong Arm in the Inflammatory Response?
Journal: International journal of molecular sciences
Published: April 01, 2018
The Timing of Immunomodulation Induced by Mesenchymal Stromal Cells Determines the Outcome of the Graft in Experimental Renal Allotransplantation.
Journal: Cell transplantation
Published: February 05, 2017
Datasets for the validation of the "in vivo" siRNA-silencing of CD40 and for the detection of new markers of atherosclerosis progression in ApoE-deficient mice.
Journal: Data in brief
Published: November 03, 2016
Silencing of CD40 in vivo reduces progression of experimental atherogenesis through an NF-κB/miR-125b axis and reveals new potential mediators in the pathogenesis of atherosclerosis.
Journal: Atherosclerosis
Published: July 24, 2016
Erratum to: JAK3-STAT pathway blocking benefits in experimental lupus nephritis.
Journal: Arthritis research & therapy
Published: June 21, 2016
RNAi-Based Therapy in Experimental Ischemia-Reperfusion Injury. The New Targets.
Journal: Current pharmaceutical design
Published: March 18, 2016
JAK3-STAT pathway blocking benefits in experimental lupus nephritis.
Journal: Arthritis research & therapy
Published: December 23, 2015
CD154-CD40 T-cell co-stimulation pathway is a key mechanism in kidney ischemia-reperfusion injury.
Journal: Kidney international
Published: June 18, 2014
Last Updated: 09/26/2026